Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers
This study is ongoing, but not recruiting participants.
Sponsored by: Salix Pharmaceuticals
Information provided by: Salix Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00622375
  Purpose

The current study is being conducted to evaluate the relative bioavailability and single- and multiple-dose pharmacokinetics of encapsulated mesalamine granules(eMG) in healthy subjects.


Condition Intervention Phase
Healthy
Drug: mesalamine
Phase I

Drug Information available for: Mesalamine
U.S. FDA Resources
Study Type: Interventional
Study Design: Basic Science, Open Label, Single Group Assignment, Pharmacokinetics Study
Official Title: A Phase I, Single- And Multiple-Dose, Relative Bioavailability and Pharmacokinetic Study of Encapsulated Mesalamine Granules Administered Orally to Healthy Volunteers

Further study details as provided by Salix Pharmaceuticals:

Primary Outcome Measures:
  • Individual pharmacokinetic parameters for mesalamine and its metabolites will be summarized with descriptive statistics [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: February 2008
Arms Assigned Interventions
1: Experimental Drug: mesalamine
encapsulated mesalamine granules

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The subject is Male, or female of Non-childbearing potentia.l
  • The subject is female of childbearing potential, who has a negative serum pregnancy test at screen and agrees to using appropriate birth control.
  • The subject is between the ages of 18 and 45 years.
  • The subject has a body mass index (BMI) between 18 and 32 kg/m2 (weight/[height]).

Exclusion Criteria:

  • The subject is seropositive for human immunodeficiency virus (HIV),hepatitis B surface antigen, and/or hepatitis C virus.
  • The subject has any clinically significant medical, social, or emotional problem.
  • The subject is pregnant or lactating
  • The subject has a history of clinically significant renal, hepatic,endocrine, oncological,gastrointestinal, or cardiovascular disease or a history of epilepsy, asthma, diabetes mellitus, psychosis, glaucoma, or severe head injury.
  • The subject is currently receiving mesalamine or aspirin containing products
  • The subject has a history of viral, bacterial, or fungal infection within 4 weeks of screening.
  • The subject has an acute illness within 1 week of study-drug administration.
  • The subject has an abnormal nutritional status, including unconventional, alternative,and abnormal diets; excessive or unusual vitamin intake; malabsorption; psychological eating disorders; difficulty swallowing medication; significant recent weight change; etc.
  • The subject has clinically significant allergies.
  • The subject has a hypersensitivity or allergy to mesalamine or other salicylate.
  • The subject has known or suspected alcohol abuse or illicit drug use within the past year
  • The subject has used tobacco (or nicotine products) during the 6 months prior to screening
  • The subject has participated in an investigational drug study within the 30 days before receiving study drug
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00622375

Locations
United States, Texas
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Salix Pharmaceuticals
Investigators
Study Director: Audrey Shaw, PhD Salix Pharmaceuticals
  More Information

Responsible Party: Salix Pharmaceuticals
Study ID Numbers: MPPK1003
Study First Received: February 14, 2008
Last Updated: February 22, 2008
ClinicalTrials.gov Identifier: NCT00622375  
Health Authority: United States: Food and Drug Administration

Keywords provided by Salix Pharmaceuticals:
Pharmacokinetic study
Healthy subjects

Study placed in the following topic categories:
Mesalamine
Healthy

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Sensory System Agents
Analgesics, Non-Narcotic
Therapeutic Uses
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Antirheumatic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009